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Abstract
Ganglioside as a neurotrophic drug has been hitherto widely used in China, although Guillain-Barre ´ syndrome (GBS)
following intravenous ganglioside treatment was reported in Europe several decades ago. We identified 7 patients who
developed GBS after intravenous use of gangliosides (ganglioside+ group) and compared their clinical data with those of 77
non-ganglioside-associated GBS patients (ganglioside2 group) in 2013, aiming at gaining the distinct features of
ganglioside-associated GBS. Although the mean age, protein levels in cerebrospinal fluid (CSF) and frequency of cranial
nerve involvement were similar between the two groups, the Hughes Functional Grading Scale (HFGS) score and the
Medical Research Council (MRC) sum score at nadir significantly differed (4.960.4 vs 3.661.0; 7.765.5 vs 36.9614.5, both p,
0.001), indicating a higher disease severity of ganglioside-associated GBS. A higher ratio of patients with ganglioside-
associated GBS required mechanical ventilation (85.7% vs 15.6%, p,0.01). The short-term prognosis of ganglioside-
associated GBS, as measured by the HFGS score and the MRC sum score at discharge, was poorer (4.360.5 vs 2.861.1;
17.3612.9 vs 46.0613.9, both p,0.001). All the patients in the ganglioside+ group presented an axonal form of GBS, namely
acute motor axonal neuropathy (AMAN). When compared with the AMAN patients in the ganglioside2 group, more severe
functional deficits at nadir and poorer recovery after standard treatment were still prominent in ganglioside-associated GBS.
Anti-GM1 and anti-GT1a antibodies were detectable in patients with AMAN while not in patients with the demyelinating
subtype of GBS. The concentrations of these antibodies in patients with AMAN were insignificantly different between the
ganglioside+ and ganglioside2 groups. In sum, ganglioside-associated GBS may be a devastating side effect of intravenous
use of gangliosides, which usually manifests a more severe clinical course and poorer outcome.
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Introduction
Guillain-Barre ´ syndrome (GBS) is an immune-mediated disor-
der in the peripheral nervous system with inflammatory infiltra-
tion, demyelination and/or axonal damage as the main patho-
logical features [1]. Depending on the involvement of nerve fiber
types (sensory, motor and autonomic) and the predominant nature
of nerve injury (demyelination or axonal degeneration), GBS can
be divided into acute inflammatory demyelinating polyneuropathy
(AIDP), acute motor axonal neuropathy (AMAN), acute motor-
sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome
(MFS) and some other relatively rare subtypes [1]. AIDP and
AMAN are the major subtypes of GBS and they are distinct from
each other in terms of immunopathogenesis, electrophysiological
findings, pathological changes and responses to treatment, etc [2].
AMAN, a pure motor axonal subtype of GBS, which was initially
identified from GBS patients in northern China [3], is more
frequent in eastern Asia and Central and South America [2].
Immunohistochemical studies on AMAN revealed antibody-
mediated damage to the motor axonal membrane suggestive of
an immune response directed against the motor axolemma [3–4].
AMASN is another axonal subtype of GBS in which axonal
degeneration involves both motor and sensory nerves [1]. AMAN
and AMASN are associated with Campylobacter jejuni enteritis
and antibodies against gangliosides [2]. High titers of anti-GM1
antibodies were found in patients who developed GBS following
exogenous gangliosides injection [5–7], leading to the suspicion
that exogenous gangliosides might be foreign to humans and may
act as an immunogenic agent. The animal model of AMAN shares
pathological features with human AMAN [8]. Despite reports on
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decades ago, which led to its withdrawal from European market
[9], ganglioside as a nutritional agent has been hitherto widely
used in China and ganglioside-associated GBS cases have been
rarely documented. Therefore, it remains unknown whether the
clinical course and the outcome of ganglioside-associated GBS are
distinguishable from non-ganglioside-associated sporadic GBS. In
this study, we identified patients who developed GBS after
receiving intravenous gangliosides and compared them with those
without receiving gangliosides, aiming to depict a distinctive
picture of ganglioside-associated GSB.
Materials and Methods
Study subjects
This study was approved by the ethics committee of the First
Hospital of Jilin University, Changchun, China. Written informed
consent was obtained from all patients. All GBS patients who were
admitted to Department of Neurology of the First Hospital of Jilin
University in 2013 were enrolled. These patients fulfilled the
diagnostic criteria for GBS [10]. The Department of Neurology of
the First Hospital of Jilin University is the largest center for the
diagnosis and treatment of neurological diseases in northeast
China. Gangliosides as an exclusive component (monosialotetra-
hexosylganglioside sodium salt injection) or part of a compound
(cattle encephalon glycoside and ignotin injection) have never been
used in our department and all the enrolled patients were referred
to our department from other departments or from other hospitals.
Patients diagnosed as MFS or chronic inflammatory demyelinat-
ing polyneuropathy (CIDP) were ruled out. Critical illness
polyneuropathy as the most common cause of acute flaccid
paralysis in hospital was also excluded [11]. All these ganglioside-
associated GBS patients received gangliosides intravenously for
treating other diseases while subsequently developed fulminant
acute polyneuropathy during or after the treatment.
Grouping and treatment
Enrolled subjects were divided into the ganglioside+ group
(ganglioside-associated) and the ganglioside2 group (non-gangli-
oside-associated) according to whether they received exogenous
gangliosides before disease onset. Diagnosis of AIDP or AMAN
was based on the electrophysiological criteria proposed by Hadden
and colleagues [12].
All patients received a standard treatment with intravenous
immunoglobulin (IVIG, 0.4 g/kg body weight per day, for 5
consecutive days), immediately clinical diagnosis was established
after admission. Patients whose functional deficits kept deteriorat-
ing despite the use of IVIG were treated with corticosteroids (pulse
methylprednisolone 1000 mg for 3 days and gradually tapered).
Evaluation of clinical severity and functional impairment
The clinical severity and functional impairment were evaluated
for all the enrolled GBS subjects. Motor function deficits of
patients were scored by the Hughes Functional Grading Scale
(HFGS) score ranging from 0 to 6. The scale was specifically
defined as follows: 0: healthy state; 1: minor symptoms and
capable of running; 2: able to walk 5 m or more without assistance
but unable to run; 3: able to walk 5 m across an open space with
help; 4: bedridden or chair bound; 5: requiring assisted ventilation
for at least part of the day; 6: dead [13]. Neurologic function was
also evaluated by using the Medical Research Council (MRC) sum
score of six bilateral muscles in arms and legs, ranging from 0
(tetraparalytic) to 60 (normal strength) [14]. Nadir of the disease
was defined as the highest HFGS score or the lowest MRC sum
score.
Figure 1. Comparisons of electrophysiological findings and functional deficits between the ganglioside+ and ganglioside2 groups.
A. Electrophysiological examinations on patients in the ganglioside+ group revealed impairment mainly to axons suggestive of acute motor axonal
neuropathy (AMAN). In the non-ganglioside-associated group (ganglioside2 group), 46 out of 77 patients (59.7%) received electrophysiological
examinations, and the ratios of acute inflammatory demyelinating polyneuropathy (AIDP) and AMAN were 56.5% and 32.6%, respectively. B. Two
patients (28.6%) in the ganglioside+ group while 29 (37.7%) in the ganglioside2 group were found with bilateral facial nerves palsy (p.0.05). The
difference did not reach statistical significance. Ventilation ratio was significantly higher in the ganglioside+ group as compared that in the
ganglioside2 group (p,0.01). C. The scores of Hughes Functional Grading Scale (HFGS) were significantly different between the ganglioside+ group
and the ganglioside2 group, both at nadir and at discharge, and higher HFGS scores were found in the ganglioside+ group (p,0.001), suggestive of
severe clinical course and poor short-term outcome. D. The Medical Research Council sum scores (MRC) were significantly lower in the ganglioside+
group both at nadir and at discharge (p,0.001).
doi:10.1371/journal.pone.0104074.g001
Table 2. Comparisons of clinical features between patients with ganglioside-associated GBS and non-ganglioside-associated GBS.
Variables Ganglioside+ group Ganglioside2 group p-value
Age (year-old) 50.6615.0 45.4615.6 .0.05
AMAN 100% (7/7) 32.6% (15/46) ,0.01
HFGS score at nadir 4.960.4 3.661.0 ,0.001
MRC sum score at nadir 7.765.5 36.9614.5 ,0.001
Ventilation 85.7% (6/7) 15.6% (12/77) =0.001 ,0.01
Cranial nerve involvement 28.6% (2/7) 37.7% (29/77) .0.05
Protein level of CSF (g/L) 1.160.7 1.261.1 .0.05
HFGS score at discharge 4.360.5 2.861.1 ,0.001
MRC sum score at discharge 17.3612.9 46.0613.9 ,0.001
GBS: Guillain-Barre ´ syndrome; AMAN: acute motor axonal neuropathy; CSF: cerebrospinal fluid; HFGS: the Hughes Functional Grading Scale; MRC: the Medical Research
Council.
doi:10.1371/journal.pone.0104074.t002
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Samples of CSF were obtained from lumbar puncture and
plasma from venous puncture after an informed consent was
acquired. CSF samples that appeared turbid or mixed with blood
were excluded. CSF and plasma samples were then aliquoted and
stored at 280uC until further analysis.
ELISA for measurement of anti-ganglioside (GM1 and
GT1a) antibodies
Paired samples of CSF and plasma were acquired from patients
with GBS. ELISA kits for detection of anti-GM1 antibodies and
anti-GT1a IgG antibodies were purchased from manufacturers
(R&D Systems, Minneapolis, MN, US), and detecting procedures
were followed according to their instructions. The kits applied the
quantitative sandwich enzyme immunoassay technique. Microtiter
plates had been pre-coated with ganglioside antigen (GM1 or
GT1a). Standards or samples were then added to the microtiter
plate wells and ganglioside antibodies would bind to the antigen
pre-coated wells. A standardized preparation of horseradish
peroxidase-conjugated ganglioside antigen was added to ‘‘sand-
wich’’ the ganglioside antibodies (anti-GM1 or anti-GT1a)
immobilized on the plate. The microtiter plates underwent 2 h
incubation, and then the wells were thoroughly washed to remove
all unbound components. Substrate solutions were then added to
each well. The enzyme (horseradish peroxidase) and substrate
were allowed to react over a short incubation period (30 min). The
reaction was terminated by adding a sulphuric acid solution and
the color change was measured spectrophotometrically at a
wavelength of 450 nm by an ELISA reader. A standard curve
was plotted relating the intensity of the color (O.D.) to the
concentration of the standards. The concentrations of ganglioside
antibodies in each sample were extrapolated from this standard
curve.
Statistical analysis
Statistical analysis was performed with SPSS version 17.0
software (SPSS, IBM, West Grove, PA, USA). Data were
expressed as mean 6 standard deviation. The Chi-square or
Fisher exact tests were used for discrete variables and the student-t
tests for continuous variables. For all statistical tests, p,0.05 was
considered significant.
Results
Demographic features of patients with ganglioside-
associated GBS
From January 1 to December 31, 2013, a total of 84 patients
with GBS, aged from 18 to 84 years old, were consecutively
enrolled in this study, among whom 58.3% were males. Subjects
were divided into the ganglioside+ group and the ganglioside2
group. Seven patients fell into the ganglioside+ group and the
detailed clinical features are shown in Table 1. Five (71.4%) of
them were males with the mean age of 50.
In the ganglioside+ group, patients developed flaccid paralysis
during or several days after ganglioside treatment for other
diseases without any antecedent infections. The interval from the
first use of gangliosides to the onset of polyneuropathy ranged
from 5 to 14 days. Six patients (85.7%) developed respiratory
muscle paralysis requiring intubation and ventilation. Two
patients (28.6%) had bilateral facial nerves palsy. Lumbar
puncture was performed in 5 patients and albumino-cytologic
dissociation of CSF was found in 4 of them (80%). Electrophys-
iological examinations revealed mainly the impairment of axons
suggestive of AMAN (Figure 1A). The HFGS score and the MRC
sum score were 4.960.4 and 7.765.5, respectively, at nadir, while
they were 4.360.5 and 17.3612.9, respectively, at discharge.
Seventy-seven subjects fell into the ganglioside2 group with the
mean age of 45. Forty-two (54.6%) of them were males. In the
ganglioside2 group, 50 (64.9%) patients developed polyneurop-
athy out of hospitals with antecedent respiratory or gastrointestinal
Figure 2. Stratified analyses of electrophysiological findings and functional deficits in patients according to subtypes (axonal form
or demyelinating form) between the ganglioside+ and ganglioside2 groups. A. Two acute motor axonal neuropathy (AMAN) patients
(28.6%) in the ganglioside+ group while 6 out of 15 (40%) in the ganglioside2 group were found with bilateral facial nerves palsy. However, the
frequency of cranial nerve involvement did not significantly differ in AMAN patients between the ganglioside+ group and ganglioside2 group. The
ventilation ratio was significantly higher in the ganglioside+ group when compared with that in the ganglioside2 group (p,0.01). B. The scores of
Hughes Functional Grading Scale (HFGS) were higher in AMAN patients in the ganglioside+ group both at nadir and at discharge suggestive of more
severe clinical course and poorer short-term outcome. C. The scores of HFGS at nadir and at discharge were insignificantly different between patients
with acute inflammatory demyelinating polyneuropathy (AIDP) and AMAN in the ganglioside2 group (both p.0.05). D. The sum score of Medical
Research Council (MRC) at nadir was significantly higher in patients with AIDP in the ganglioside2 group than AMAN (p,0.05).
doi:10.1371/journal.pone.0104074.g002
Table 3. Comparisons of clinical features of AMAN patients between the ganglioside+ group and the ganglioside2 group.
Variables Ganglioside+ group (7/7) Ganglioside2 group (15/77) p-value
Age (year-old) 50.6615.0 48.3616.4 .0.05
HFGS score at nadir 4.960.4 3.960.9 =0.013 ,0.05
MRC sum score at nadir 7.765.5 32.3616.5 =0.001 ,0.01
Ventilation ratio 85.7% (6/7) 20% (3/15) =0.007 ,0.01
Cranial nerve involvement 28.6% (2/7) 40% (6/15) .0.05
Protein level in CSF (g/L) 1.160.7 1.160.6 .0.05
HFGS score at discharge 4.360.5 2.961.1 =0.001 ,0.01
MRC sum score at discharge 17.3612.9 43.0614.9 =0.001 ,0.01
AMAN: acute motor axonal neuropathy; HFGS: the Hughes Functional Grading Scale; MRC: the Medical Research Council; CSF: cerebrospinal fluid.
doi:10.1371/journal.pone.0104074.t003
A Comparative Study on GBS
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Respiratory muscle paralysis requiring intubation and ventilation
was found in 12 patients (15.6%) and cranial nerve involvement
was found in 29 patients (37.7%). Lumbar puncture was
performed in 63 patients. Albumino-cytologic dissociation of
CSF was found in 41 patients (65.1%) while normal protein
concentrations in CSF were found in 8 patients (12.7%).
Interestingly, slight pleocytosis with increased concentrations of
protein was found in 14 patients (22.2%). Electrophysiological
examination was performed in 46 patients (59.7%). The distribu-
tion of the subtypes of GBS in the ganglioside2 group is showed in
Figure 1A. The HFGS score and the MRC sum score were
3.661.0 and 36.9614.5 respectively at nadir while were 2.861.1
and 46.0613.9 respectively at discharge.
More severe clinical course and poorer short-term
prognosis of ganglioside-associated GBS
The comparisons of the clinical features between the two groups
are showed in Table 2. The age and cranial nerve involvement as
showed in Figure 1B, and protein concentrations in CSF of the
two groups were not different. Higher HFGS and lower MRC
scores were noted in the ganglioside+ group both at nadir and at
discharge (Figure 1C and D), suggestive of a severe clinical course
and poor outcome in the ganglioside+ group. Additionally,
respiratory muscle paralysis requiring intubation and ventilation
was more frequent in the ganglioside+ group, which was shown in
Figure 1B.
More severe clinical course and poorer short-term
prognosis of ganglioside-associated AMAN compared
with non-ganglioside-associated AMAN
Given the fact that all patients presented an axonal form of
GBS, i.e. AMAN in the ganglioside+ group, we further compared
the clinical features between the AMAN patients in the
ganglioside+ group and in the ganglioside2 group. The results
are shown in Table 3. The age, the ratio of cranial nerve
involvement and the protein level in CSF were insignificantly
different between the two groups (Figure 2A). The scores of HFGS
at nadir and at discharge of patients with AMAN (Figure 2B),
significantly differed between the two groups, indicating a severe
clinical course of AMAN patients following ganglioside treatment.
Likewise, the MRC sum scores at nadir and at discharge were
different between the two groups as well suggestive of a severe
clinical course and poor outcome of AMAN in the ganglioside+
group. Additionally, respiratory muscle paralysis requiring intu-
bation and ventilation was more frequent in the ganglioside+
group (Figure 2A). The mean hospitalization duration of the
AMAN patients was 60 and 22 days in the ganglioside+ group and
in the ganglioside2 group, respectively.
Comparisons between AIDP and AMAN patients in the
ganglioside2 group
Forty-six patients received electrophysiological examinations to
identify the clinical subtypes and 41 patients could be categorized
as either AIDP or AMAN. The clinical features of AIDP and
AMAN in the ganglioside2 group are shown in Table 4. The age,
the frequency of cranial nerve involvement, the ventilation ratio
and the concentrations of protein in CSF were similar between the
two groups. The HFGS score and the MRC sum score were
displayed in Figure 2C and D. The MRC sum score at nadir was
significantly higher in patients with AIDP than in the patients with
AMAN.
Anti-ganglioside antibodies in CSF and plasma of AMAN
patients
Anti-GM1 and anti-GT1a antibodies were detectable in AMAN
patients. However, neither of them was detectable in AIDP
patients. The concentrations of anti-GM1 antibodies of AMAN
patients in the ganglioside+ group and in the ganglioside2 group
were 288.36116.9 ng/L and 232.66154.8 ng/L, respectively, in
plasma (p.0.05), and 9.961.6 ng/L and 10.662.8 ng/L, respec-
tively, in CSF (p.0.05). The concentrations of anti-GT1a
antibodies of AMAN patients in the ganglioside+ group and in
the ganglioside2 group were 320.26157.5 ng/L and
238.76130.7 ng/L, respectively, in plasma (p.0.05), and
34.767.8 ng/L and 21.364.6 ng/L, respectively, in CSF (p.
0.05).
Correlation analysis revealed negative results between clinical
severity scores and concentrations of anti-ganglioside antibodies in
CSF and plasma of AMAN patients, both in the ganglioside+
group and in the ganglioside2 group.
Discussion
Gangliosides have long been intravenously used as a neuro-
trophic drug in China. Despite safety concern aroused in Europe
several decades ago [9], intravenous use of gangliosides in China
has been believed to be safe and GBS as a severe side effect of this
Table 4. Comparisons of clinical features between AIDP and AMAN patients in the ganglioside2 group.
Variables AIDP (26) AMAN (15) p-value
Age (year-old) 44.6611.6 48.3616.4 .0.05
HFGS score at nadir 3.661.0 3.960.9 .0.05
MRC sum score at nadir 40.969.8 32.3616.5 =0.042 ,0.05
Ventilation ratio 15.4% (4/26) 20% (3/15) .0.05
Electrophysiology Demyelination Axonal damage N/A
Cranial nerve involvement 38.5% (10/26) 40% (6/15) .0.05
Protein level in CSF (g/L) 1.161.2 1.160.6 .0.05
HFGS score at discharge 2.561.0 2.961.1 .0.05
MRC sum score at discharge 50.767.08 43.0614.9 .0.05
AIDP: acute inflammatory demyelinating polyneuropathy; AMAN: acute motor axonal neuropathy; HFGS: the Hughes Functional Grading Scale; MRC: the Medical
Research Council; CSF: cerebrospinal fluid.
doi:10.1371/journal.pone.0104074.t004
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case series of 7 patients who developed GBS after intravenous use
of gangliosides. All these patients presented an axonal form of
GBS, remarkably higher severity and poorer short-term prognosis.
The association between exogenous gangliosides and GBS was
further evidenced by the positivity of anti-GM1 and anti-GT1a
antibodies in CSF and plasma, the albumino-cytologic dissociation
of CSF and the result of the electrophysiological examination.
Although rare, GBS may occur following noninfectious events.
Among various noninfectious factors associated with GBS, the
most interesting one is exogenous gangliosides [15–16]. It had
been extensively prescribed in various countries mainly for the
treatment of peripheral neuropathies because of its neurotrophic
role in neural regeneration [15]. However, numerous cases of GBS
after ganglioside treatment raised the suspicion that exogenous
gangliosides may cause GBS [9,16]. Clinical monitoring studies on
the relationship between exogenous gangliosides and GBS were
hence conducted. However, the relationship remains controversial
[17–21].
Although the pathogenesis of GBS secondary to gangliosides
treatment was incompletely clarified, high titers of anti-GM1
antibodies were found in some of the patients who developed GBS
after receiving a ganglioside therapy, leading to the suspicion that
exogenous gangliosides might be foreign to humans and might be
neuritogenic in humans [5–7]. Molecular mimicry has been
proposed to explain the pathogenesis of Campylobacter jejuni
associated GBS with positive antibodies against self-gangliosides
[22–23]. Therefore, we postulate that development of GBS
following gangliosides treatment might share a homologous
pathogenesis with Campylobacter jejuni associated GBS. In Odaka
et al’s study on antibodies to GBS following gangliosides therapy,
they found that GM1 is the major immunogen [7]. Further
absorption studies and secondary ion mass spectra revealed the
possible role of gangliosides in ganglioside-associated GBS [7].
Yuki and colleagues succeeded in establishing an AMAN model by
sensitizing Japanese white rabbits with a bovine brain ganglioside
mixture [8]. These rabbits developed high titers of anti-GM1 IgG
antibody [8]. Moreover, the pathological findings showed
predominant Wallerian-like degeneration with neither lymphocyt-
ic infiltration nor demyelination which was similar to the
pathological changes with AMAN [8].
It is noteworthy that gangliosides have been widely used in
China for many years. However, there has been no report on
development of GBS in China thus far. It remains unclear why the
seven patients developed GBS after gangliosides treatment among
numerous patients who received intravenous gangliosides. One
explanation is that the individual’s genetic background might
contribute to the development of GBS. It is also likely that trace
amounts of endotoxin, for instance, might contribute to the
development of GBS by acting as adjuvants in these patients.
Contamination with bacterial components has been reported in
the production process of recombinant human heat shock proteins
[24–25]. The less purified gangliosides might trigger GBS via
alteration of individual’s susceptibility in a way of ‘‘molecular
mimicry’’, and led to the occurrence of disease [22–23]. Since
GBS is an immune-mediated disorder [1], altered immune
function resulting from various diseases in the 7 patients of the
ganglioside+ group may play a synergistic role in the pathogenesis
of GBS. Quality control for ganglioside production and intensified
monitoring for side effects are therefore strongly suggested for the
safe use of gangliosides in China.
Limitations of our study include the relatively small sample size,
the failure to identify the subtypes of anti-ganglioside antibodies
and the retrospective nature of data collection. The functional
scores as measured with HFGS and the MRC sum score might be
confounded by the motor deficits before the onset of GBS.
However, this first-ever reported case series of ganglioside-
assoicated GBS in China may alert us to this devastating side
effect of intravenous use of gangliosides. Further studies are
warranted to clarify the underlying pathogenesis of ganglioside-
assoicated GBS.
In sum, exogenous gangliosides may be associated with
development of GBS due to incompletely recognized pathogenesis.
Ganglioside-associated GBS is more severe in clinical course with
poorer short-term prognosis as compared with non-ganglioside-
associated GBS in northeast China.
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